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ABSTRACT
Every bulky lesion in DNA can potentially inhibit the Taq
DNA polymerase and thereby decrease the
amplification produced in the polymerase chain
reaction. We investigated the feasibility of using this
inhibition to quantify DNA lesions produced by the
anticancer drug cisplatin. Products were detected by
electrophoresis followed by ethidium bromide staining.
Quantitation was obtained by including [32P]dCTP in
the amplification reaction and subsequently assessing
the incorporated radioactivity. Hamster genomic DNA
was platinated in vitro to defined levels and amplified
with primers that produce either a 150, 750 or 2,000
base pair fragment. The degree of inhibition of PCR
agreed with the predicted level of DNA platination in
each size of fragment, suggesting that the polymerase
was inhibited by every cisplatin-induced lesion. This
method was used to detect cisplatin-induced lesions
in the adenine phosphoribosyltransferase gene of CHO
cells. Cells were incubated with 0 - 125 zM cisplatin for
2 h, the DNA was purified and subjected to PCR. A
significant decrease in amplification of the 2 kbp
fragment was observed in DNA from cells incubated
with cisplatin at 75 1M. The degree of inhibition agreed
closely with the amount of DNA damage in the overall
genome as measured by atomic absorption. No change
was detected in amplification of the 150 base fragment
which can therefore be used to normalize data for any
variations between DNA samples. This assay has the
same sensitivity as other methods currently used for
the analysis of gene-specific damage. The advantage
of this assay is that it obviates the need for specific
endonuclease complexes to recognize and cleave DNA
adducts as previously required when analyzing damage
in specific genomic sequences.
INTRODUCTION
Studies correlating DNA damage with cytotoxicity have generally
assumed homogeneity in the distribution of damage. Various
studies on carcinogens, however, have shown that DNA damage
can occur in a non-random manner (1). Furthermore, DNA repair
can also vary throughout the genome. It has been shown that
actively transcribed genes can be repaired more efficiently than
untranscribed regions (1). This is particularly true for UV-induced
DNA damage. The formation of pyrimidine dimers in specific

genes can be measured using the dimer-specific enzyme T4
endonuclease V. This enzyme introduces a single strand break
at the site of the damage. DNA from UV-irradiated cells is
digested with an appropriate restriction endonuclease, cleaved
with T4 endonuclease V, denatured and electrophoresed.
Southern hybridization is used to identify the amount of full length
single-strand DNA of any gene of interest: the intensity of
hybridization reflects the amount of undamaged DNA. To
measure gene specific damage induced by other agents,
particularly those that produce bulky lesions in DNA, it is
necessary to use the E. coli uvrABC excinuclease complex that
recognizes and incises at a broad spectrum of DNA lesions (2).
Cisplatin is a major anticancer drug that elicits its cytotoxicity
as a consequence of producing bifunctional lesions in DNA; these
lesions are predominantly DNA intrastrand cross-links but DNA
interstrand cross-links are also formed (3). We have previously
established that mouse L1210 cells resistant to cisplatin exhibit
enhanced DNA repair (4,5). Enhanced DNA repair has
subsequently been observed in human ovarian carcinoma cells
(6). Recent work has also shown that cisplatin lesions may be
repaired preferentially from transcribed regions of the genome
(7), and furthermore, that this may contribute to the altered repair
observed in resistant cells (8). The detection of cisplatin lesions
in specific genes has required the use of the uvrABC excinuclease
complex although it appears to cleave at less than 30% of the
cisplatin lesions (7). The polymerase chain reaction can be used
as an alternative approach to measuring gene-specific damage
and has the advantage of not requiring specific damagerecognition endonucleases. To date, this method has only been
reported for the measurment of UV-induced lesions (9), but the
sensitivity was far inferior to that for the T4 endonuclease Vdependent method. Here we describe the development of this
method to detect cisplatin lesions in DNA and demonstrate that
it has at least as good sensitivity as the uvrABC excinucleasedependent method. The advantage of this method is that it requires
no specific enzymes to recognize and cleave DNA adducts, and
therefore will facilitate studies in many different laboratories.

METHODS
Cell culture
Chinese hamster ovary (CHO) cells were grown as described
previously (10). Cells (107) were plated in 160 mm culture
dishes. The following day the media was replaced with serumfree medium containing the required concentration of cisplatin.
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The cells were incubated at 37°C for 2 h, harvested by scraping
and washed twice with phosphate buffered saline. DNA was
purified by cell lysis, protease digestion and phenol extraction
(11). After ethanol precipitation, the purified DNA was
redissolved in 10 mM tris/1 mM EDTA and digested overnight
with Kpn I (BRL Life Technologies) in the suppliers
recommended buffer. This digestion reduces the viscosity of the
DNA without cleaving the sequences to be amplified. DNA was
reprecipitated with ethanol, dissolved in water and the
concentration was determined by fluorimetry using Hoechst
33258 dye (12). The samples were diluted to 25 ,ug/ml and the
concentration was confirmed by fluorimetry. The level of DNA
platination was also determined by flameless atomic absorption
spectrometry.
In vitro platination of DNA
Undamaged DNA was purified from CHO cells and then
platinated to defined levels as previously described (13).

Polymerase chain reaction
The following primers derived from the hamster adenine phosphoribosyltransferase gene were synthesized. The numbers refer
to the position in the published sequence (14). The designation
'F' represents the forward primer derived from the sense strand,
and 'R' represents the reverse primer derived from the antisense
strand. 33 IF: GTTCCCGGAC TGGTATGACC. 1620F: GGTCAATACT ATTCACTCAA 2194F: CAGCTACAGG CTGAGGTGGT. 2350R: GTTCAACCGT AGATGCTGAG. 2370R:
TTTGGTAAGG CTGAGCCACT. Amplification of a 2 kbp
fragment was obtained with primers 33 IF and 2370R; the 750
bp was obtained with 1620F and 2370R; and the 150 bp fragment
was obtained with 2194F and 2350R.
A typical 50 ,ul reaction contained 50 mM KCl, 10 mM Tris,
pH 8.3, 1.5 mM MgCl2, 0.01 % gelatin, 200 ixM of each dNTP,
1 ltM of each primer, 0.5td AmpliTaq (Perkin-Elmer Cetus) and
500 ng DNA. The amplification protocols varied with the specific
sequence to be amplified and are detailed in Table 1. In all cases
the initial denaturation was at 94°C for 4 min. Amplification was
usually for 23 cycles followed by an extra annealing and extension
at 72°C. To confirm that the extent of amplification remained
directly dependent upon the amount of amplifiable sequence, a
control reaction with a two fold dilution of undamaged DNA
(C/2) was included in most experiments. In all cases this produced
an amplification that was half of the normal dilution of undamaged

with water for 20 min to remove background radiation, then the
gel was dried and autoradiographed for 12-24 h. Quantitation
was performed on a Betascope 603 Blot Analyzer (Betagen,
Waltham, MA).

RESULTS
To quantify DNA damage by PCR, it is essential that the substrate
DNA is the limiting component in the reaction. Initial experiments
were designed to determine the number of cycles that could
provide quantitative amplification. For these experiments, the 150
bp fragment was amplified for 20-40 cycles and the products
were detected by electrophoresis followed by staining with
ethidium bromide (Fig. 1). The amplification signal increased
from almost undetectable at 20 cycles to maximum at 30 cycles
with no further increase up to 40 cycles. Up to 26 cycles, the
amount of product appeared to double with each additional cycle.
In addition, many other unexpected bands were observed at and
above 26 cycles. Similar results were observed with the 2 kbp
fragment except that the product decreased beyond 29 cycles
presumably due to continued denaturation of the product without
reannealing (not shown). It was further shown that the amount
of product increased linearly with DNA concentration between
100-500 ng (not shown). Based on these results, subsequent
experiments were performed with 500 ng DNA and for 23 cycles
of amplification. In many experiments, one reaction was
performed with 250 ng undamaged DNA (C/2) to confirm that
the amplification obtained was 50% of that obtained with
500 ng undamaged DNA.
Experiments were designed to determine whether the amount
of amplification of a specific DNA fragment was directly related
to the level of DNA platination. DNA was purified from undamaged CHO cells and platinated to defined levels. This DNA
was then subjected to PCR using primers spanning a 150 bp,
750 bp or 2 kbp fragment of the adenine phosphoribosyltransferase gene. Amplification was detected by ethidium bromide
staining. Amplification of the 2 kbp fragment was clearly inhibited
by DNA damage: at a level of 5 Pt/ 10 kb, which corresponds
to 1 Pt adduct every 2 kb, the amplified fragment was barely
visible (Fig. 2). Amplification of the 750 bp fragment was barely
visible when platinated to 10 Pt/10 kb, whereas amplification
of the 150 bp fragment was only slightly reduced at 40 Pt/10
kb. These results demonstrate that the sensitivity for detection
of DNA damage is related to the size of the fragment amplified.

DNA.

The reaction products was separated on a 1 % (2 kbp), 1.2%
(750 bp) or 2% (150 bp) agarose gel and the products visualized
by ethidium bromide staining. The molecular weight standards
used were either BstE H digested lambda DNA or Msp I digested

pBR322. For quantitative analysis, 2 jCi c[32P]-dCTP was
included in the reaction mixture, 25 pl of the reaction mixture
was separated by electrophoresis, the gel front containing
unincorporated radioactivity was cut off, the gel was washed twice
Table 1. Amplification protocols used in the current experiments
denaturation 94°C

Time in seconds
annealing 55°C

extension 72°C

90
70
60

60
60
60

120
90
60

Fragment size

2,000 bp
750 bp
150 bp

Figure 1. Determination of the conditions to use for quantitative PCR. 500 ng
CR0 genomic DNA was amplified for the indicated number of cycles using
primers for the 150 bp sequence. The PCR products were separated by
electrophoresis and stained with ethidium bromide.
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To more accurately quantify the amount of amplification, a
tracer amount of c[32P]-dCTP was included in the reaction
mixture. The resulting electrophoresis gels were autoradiographed
and the radioactivity in the amplified bands was quantified. The
results from amplification of the 2 kbp and 750 bp fragments
are shown in Fig 3. One Pt adduct/DNA strand should be
adequate to prevent amplification if every lesion blocks the Taq
DNA polymerase. As DNA was platinated randomly, the distribution of damage fits a Poisson distribution. Accordingly, at
a mean level of platination of one Pt adduct/DNA strand, 37%
of the strands remain undamaged and can be amplified. The
expected and observed values are presented in Table 2. The
correlation between these two values is very close demonstrating
that the Taq polymerase is blocked by at least the majority of
lesions in DNA. This demonstrates the validity of this method
to quantify DNA damage induced by cisplatin.
This method was applied to CHO cells that had been incubated
with 0-125 ,tM cisplatin to determine whether the DNA damage
was detectable. The ethidium bromide staining showed a
significant reduction in amplification of the 2 kbp fragment at
and above 75 yM cisplatin (Fig. 4). A parallel reaction was
performed containing a[32P]-dCTP (Fig. 5) and the radioactivity
was quantified. The results show, for example, that the
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Figure 3. Quantitation of the PCR amplification of DNA damaged with cisplatin
in vitro (fig. 2). a[32P]-dCTP was included in the PCR step, and the products
were separated by electrophoresis and autoradiographed (insets). The radioactivity
was quantified and graphed.
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Table 2. Calculation of the amount of damage expected in DNA platinated in
vitro compared to that observed by inhibition of PCR

Pt/10,000 bases Pt/2,000 bases

750 bp

undamaged

Pt
0

1

/

10,000 bases
2

5

10

20 40

cn

0
1
2

5

0
0.2
0.4
1

Figure 2. PCR amplification of DNA damaged with cisplatin in vitro to defined
levels. The PCR products were separated by electrophoresis and stained with

100
82
67
37

100
78
53
17

Pt/10,000 bases Pt/750 bases

% of 750 b
% of 750 b
sequence expected sequence
to be undamaged* observed to be
undamaged

0
1
5
10

100
92
68
47
22
5

150 bp

ethidium bromide.

% of 2 kb
% of 2 kb
sequence expected sequence
to be undamaged* observed to be

20
40

0
0.075
0.375
0.75
1.5
3

100
95
51
38
24
13

*expected values calculated according to Poisson distribution.
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radioactive signal at 125 /tM was reduced to 15% which
corresponds to an adduct level of 1.8 Pt/2 kb (Table 3). The same
DNA samples were analyzed by atomic absorption and the level
of platination agreed closely with both techniques.
It is also important to ensure that inhibition of amplification
is due to DNA damage and not to inter-sample variation that may
arise during DNA purification or from assessing DNA
concentration. This can be examined in every sample by
amplification of a fragment that is too small to have accumulated
significant damage. A 150 bp fragment was amplified and showed
no significant inhibition of amplification up to 125 AM cisplatin

(Fig. 4).
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One application of the method described here is the
confirmation of Pt damage on short DNA fragments. In other
studies, we have used the 150 bp fragment in band shift assays
to detect proteins that recognize cisplatin-damaged DNA
(unpublished). The purified 150 bp fragment obtained by PCR
was incubated with various amounts of cisplatin. In these
experiments, 60 ng of fragment was incubated with various
concentrations of cisplatin in water for 48 h in a total volume
of 9 /tl. The platinated fragment (0.2 ng) was then subjected to
10 rounds of amplification. Only at the highest level of damage
(rf = 0.25) was inhibition of amplification observed and this
inhibition corresponded to 2-4 Pt/150 bp fragment (Fig. 6). This
was far less than the 75 Pt/ 150 bp fragment which was expected
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Figure 5. Quantitation of the PCR amplification of DNA purified from CHO
cells incubated with cisplatin (fig. 4). a[32P]-dCTP was included in the PCR step,
and duplicate products were separated by electrophoresis and autoradiographed.
The radioactivity was quantified and graphed.
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Figure 4. PCR amplification of DNA purified from CHO cells that had been
incubated for 2 h with 0- 125 tiM cisplatin. The PCR products were separated
by electrophoresis and stained with ethidium bromide.
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Table 3. Comparison of the amount of DNA platination in cells incubated with
cisplatin detected by atomic absorption and by inhibition of PCR
concentration of cisplatin Pt/2,000 bases
determined by atomic
(UM)
absorption

Pt/2,000 bases calculated
from PCR

50
75
100
125

0
0.74
1.37
1.85

0.49
0.46
1.07
1.66

Figure 6. Determination of the damage introduced into a 150 bp fragment of
DNA during an in vitro incubation with cisplatin. The t50 bp fragment was
incubated with cisplatin either alone or diluted with excess of salmon testis DNA.
rf refers to the molar ratio of cisplatin to DNA nucleotide during the platination
reaction.
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because DNA platination usually approaches 100% of available
cisplatin. A subsequent experiment was performed in which 30
ng of 150 bp fragment was mixed with 120 isg salmon testis DNA
and incubated with various concentrations of cisplatin in a final
volume of 92 ,ul. In this experiment the same molar ratio of
cisplatin to DNA was used, but higher concentrations of both
were used compared to the previous experiment. After PCR, it
was evident that a much greater inhibition of amplification was
obtained indicating much higher levels of platination of the 150
bp fragment (Fig. 5). These results demonstrate that at low
concentrations of DNA and cisplatin, other minor components
of an incubation can compete with DNA for reaction with
cisplatin. Therefore PCR is a useful method to assure damage
at low concentrations of DNA and cisplatin.

DISCUSSION
We have demonstrated in this paper that PCR can be used to
quantify damage induced in DNA by cisplatin. Using DNA with
defined levels of damage, inhibition of PCR was observed to an
extent that suggested the Taq DNA polymerase was inhibited at
every Pt lesion. About 65 % of the lesions in DNA are intrastrand
cross-links at the sequence d(GpG), while 25% occurs at d(ApG)
and about 6% at dGpNpG) (where N is any nucleotide) (3). Only
about 1% of the lesions represent DNA interstrand cross-linksand
are therefore too rare to contribute to the observed results. It
is feasible that a low percentage of lesions could be by-passed
by the polymerase but this would not be detected by this assay
and would not contribute significantly to quantitation of the lesions
in DNA. In cells that were platinated in culture, inhibition of
PCR was also observed and this agreed closely with the amount
of DNA damage measured directly by atomic absorption.
Therefore, under these conditions, the only detectable blocks to
PCR were the Pt lesions.
The sensitivity for detection of DNA damage is dependent upon
the size of the target sequence. At any level of platination, there
is a greater probability that an adduct lies within a 2 kbp region
than within a 150 bp sequence. Therefore, amplification of the
longer fragment is expected to be more inhibited than the shorter
fragment or, to express it another way, higher amounts of damage
must be introduced into a short fragment to produce an equivalent
inhibition of amplification. This agrees very well with the
experimental observations. It should be possible to increase the
sensitivity of the assay by increasing the size of the fragment
to be amplified. However, the longest sequence that we are aware
of that has been successfully amplified is 10.2 kbp but the
efficiency of amplification decreased markedly with increasing
size of fragment (15). This suggests that little increase in
sensitivity can be obtained in practical terms by increasing the
target size much further than the 2 kbp used here.
There is always concern for potential variations in the efficiency
of amplification between various DNA preparations. Such
variations may arise from contamination in samples, quantitation
of DNA, or fluctuations in the amplification reaction. This can
be accounted for in the current protocol by amplification of a
150 bp fragment. This acts effectively as a control because it
will have insufficient damage to inhibit PCR. In the current
experiments, no variation in amplification of the 150 bp fragment
was observed in DNA purified from cells. However, should
variations be observed, it would be easy to normalize the
amplification of the large fragment to that observed for the small
fragment. Furthermore, with appropriate selection of primers,

it would be feasible to amplify fragments of different sizes and
from different genes in a single reaction. This was not possible
in the current experiments because the smaller fragments were
contained within the larger fragments, and therefore would have
been amplified from the product of the other amplifications.
In these experiments, we were able to detect damage in cells
incubated with 75 ,uM cisplatin. The LCgo for a 2 h incubation
of these cells in cisplatin is 30 yM (10) so the cells had to be
incubated with greater than a 99% lethal concentration before
lesions were detectable. Using the uvrABC complex to detect
cisplatin lesions in specific genes of CHO cells, a 1 h incubation
with 100-300 /tM cisplatin was used (7). Therefore the
sensitivity of the current assay appears to be as good as the
previously available method. In the experiments with uvrABC,
the target gene was up to 23 kbp, hence a greater sensitivity would
be expected. The fact that greater sensitivity was not seen can
in part be attributed to the endonuclease complex cleaving at only
30% of the lesions (7), whereas the Taq DNA polymerase appears
to stop at every lesion.
The original experiments on gene-specific damage were
performed with UV-damaged DNA. Incisions were made at the
site of pyrimidine dimers using T4 endonuclease V, then the DNA
was denatured and analyzed by Southern hybridization. In those
experiments, DNA damage was detected at 10-20 J/m2 while
the LCgo value was 15 J/m2 (16). Hence, the lesions were
detectable at somewhat less toxic concentrations than for cisplatin.
It can be reasoned that it takes less cisplatin lesions than UVinduced dimers to kill cells.
A recent paper has also demonstrated the use of PCR to detect
damage in specific genes, but in this case they studied UV-induced
DNA damage (9). A 50% inhibition of PCR was observed in
cells irradiated with 6 kJ/m2. Surprisingly, this inhibition was
independent of the size of the sequence amplified; in their case
the sequences were 147-440 bp. The radiation required to bring
about this inhibition of PCR was 600 fold higher than required
to detect gene-specific damage using T4 endonuclease V (16).
This is in part due to the smaller size of the target analyzed, 440
bp rather than 9-23 kbp used in the endonuclease studies. It
may also suggest that the Taq DNA polymerase does not stop
at every pyrimidine dimer. It was previously demonstrated that
UV-irradiation of CHO cells with 10 J/m2 produced one
endonuclease-sensitive site/20 kb of the dhfr gene (17). This is
in close agreement with the calculated value of 0.8 endonuclease
sensitive sites/108 daltons/J/m2 for the overall CHO genome
(18). This calculates to 1 pyrimidine dimer/8 bases at 24 kJ/m2.
This is considerably more damage than the 2-3 pyrimidine
dimers per 440 bp fragment calculated by Govan et al for a
radiation dose of 24 kJ/m2 (9). A likely explanation for these
discrepancies is that the previous report started with 100 ng DNA
and used 40 cycles of PCR which should be far beyond the
exponential phase of amplification.
Most of the studies on damage in specific genes are designed
to investigate the potentially different rates of DNA repair in these
genes. The toxicity of the agent under investigation is therefore
of particular concern. All of the methods used to date require
that toxic conditions be used. For UV-unduced DNA damage,
it is necessary to use -90% lethal irradiation, and for cisplatin,
it requires -99% lethal concentration. It is feasible that these
conditions could considerably alter the kinetics of repair or even
the genomic domains that are repaired. The different toxicities
required for each agent may explain why gene-specific or strandspecific DNA repair is not observed for all agents. Perhaps more
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significant is the concern that the repair that is observed is
occurring in cells that are destined to die. Although the cell
membranes may still be intact as assayed by trypan blue
exclusion, it is known that genomic DNA is digested by
endonucleases in dying cells long before any indication of changes
in membrane integrity (19,20). For example, in experiments not
shown, the CHO cells incubated with cisplatin above have been
further incubated for 24 h in the absence of drug to permit DNA
repair. At drug concentrations above 25 ,tM, the genomic DNA
had been cleaved to fragments of 180 bp or oligomers of this
length. These fragments are characteristic of the internucleosomal
digestion of DNA associated with cell death by apoptosis. Little
attention has been given to this concern. Presumably, the
degraded DNA was excluded from the analysis. In ongoing
studies, we have found that murine leukemia L1210 cells are more
resistant to endonuclease digestion associated with cell death, and
that gene-specific damage and repair can be assessed with this
PCR-based method.
In summary, the PCR-based method for measuring genespecific damage appears to be as sensitive as other available
techniques. Its major advantage is that it requires no specific
enzymes to recognize and cleave DNA adducts. The uvrABC
excinuclease complex used for such studies is not generally
available and the current method will therefore provide a very
convenient alternative method.
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